688315 logo

Novogene XSSC:688315 Stock Report

Last Price

CN¥12.88

Market Cap

CN¥5.2b

7D

-3.1%

1Y

-48.1%

Updated

26 Nov, 2024

Data

Company Financials +

688315 Stock Overview

Provides genomic services and solutions worldwide. More details

688315 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Rewards

Risk Analysis

No risks detected for 688315 from our risk checks.

Novogene Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novogene
Historical stock prices
Current Share PriceCN¥12.88
52 Week HighCN¥25.21
52 Week LowCN¥9.03
Beta0.83
11 Month Change-6.53%
3 Month Change33.47%
1 Year Change-48.11%
33 Year Changen/a
5 Year Changen/a
Change since IPO-57.89%

Recent News & Updates

Recent updates

Shareholder Returns

688315CN Life SciencesCN Market
7D-3.1%-0.8%-0.6%
1Y-48.1%-31.4%3.2%

Return vs Industry: 688315 underperformed the CN Life Sciences industry which returned -31.4% over the past year.

Return vs Market: 688315 underperformed the CN Market which returned 3.2% over the past year.

Price Volatility

Is 688315's price volatile compared to industry and market?
688315 volatility
688315 Average Weekly Movement10.3%
Life Sciences Industry Average Movement10.5%
Market Average Movement8.4%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 688315 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688315's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20112,144Ruiqiang Liwww.novogene.com

Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples.

Novogene Co., Ltd. Fundamentals Summary

How do Novogene's earnings and revenue compare to its market cap?
688315 fundamental statistics
Market capCN¥5.22b
Earnings (TTM)CN¥187.24m
Revenue (TTM)CN¥2.09b

27.9x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688315 income statement (TTM)
RevenueCN¥2.09b
Cost of RevenueCN¥1.21b
Gross ProfitCN¥885.56m
Other ExpensesCN¥698.32m
EarningsCN¥187.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Nov 29, 2024

Earnings per share (EPS)0.46
Gross Margin42.33%
Net Profit Margin8.95%
Debt/Equity Ratio0%

How did 688315 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

10%

Payout Ratio